Ventus is applying structural immunology to discover and develop therapeutics targeting innate immune pathways to address human disease.
Total raised: $300M
Founded date: 2019
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.02.2022 | Series C | $140M | RA Capital... |
| 08.04.2021 | Series B | $100M | - |
| 06.05.2020 | Series A | $60M | - |
Mentions in press and media 7
| Date | Title | Description |
| 09.02.2022 | Ventus Therapeutics Closes $140 Million Series C Financing | Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule therapeutics across a broad range of disease indications, announced today the closing of a $1... |
| 09.02.2022 | Ventus Therapeutics Closes $140M Series C Financing Round | Ventus Therapeutics, Inc., a Waltham, MA- and Montreal, QC, Canada-based biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule therapeutics across a broad range of disease indi... |
| 08.04.2021 | Ventus Therapeutics Closes $100 Million Series B Financing | Ventus Therapeutics, Inc., a biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, today announced a $100 million Series B financing led by RA Capital M... |
| 08.04.2021 | Ventus Therapeutics Raises $100M in Series B Financing | Ventus Therapeutics, Inc., a Boston, Massachusetts and Montreal, Canada-based biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, raised $100m in Seri... |
| 06.05.2020 | Ventus Therapeutics Raises $60M in Series A Funding | Ventus Therapeutics, a Waltham, Mass. and Montreal, Canada-based a biopharmaceutical company, raised $60m in Series A financing. The round was led by founding investor Versant Ventures with participation from GV (formerly Google Ventures). ... |
| 06.05.2020 | Ventus Therapeutics Launches with $60 Million Series A | WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics Inc. today announced a $60 million Series A financing led by founding investor Versant Ventures with participation by GV (formerly Google Ventures). Proceeds will be used t... |
| - | Ventus Therapeutics | “Ventus is applying structural immunology to discover and develop therapeutics targeting innate immune pathways to address human disease.” |